Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,018 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Health-related quality of life with daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible patients with newly diagnosed multiple myeloma: analysis of the phase 3 OCTANS study.
Fu W, Bang SM, Huang H, Kim K, Li W, An G, Lee JJ, Cai Z, Jin J, Wang Y, Chim CS, Carson R, Liu R, Zhao M, Chen X, Cui C, Hou J, Wang J. Fu W, et al. Among authors: cui c. Ann Hematol. 2025 May;104(5):2765-2776. doi: 10.1007/s00277-025-06303-3. Epub 2025 May 23. Ann Hematol. 2025. PMID: 40407887 Free PMC article. Clinical Trial.
Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study.
Fu W, Bang SM, Huang H, Kim K, Li W, An G, Lee JJ, Cai Z, Jin J, Wang Y, Chim CS, Carson R, Liu R, Zhao M, Chen X, Cui C, Hou J, Wang J. Fu W, et al. Among authors: cui c. Ann Hematol. 2025 Jan;104(1):515-525. doi: 10.1007/s00277-024-05958-8. Epub 2024 Sep 4. Ann Hematol. 2025. PMID: 39227450 Free PMC article. Clinical Trial.
Correction to: Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS study.
Fu W, Bang SM, Huang H, Kim K, Li W, An G, Lee JJ, Cai Z, Jin J, Wang Y, Chim CS, Carson R, Liu R, Zhao M, Chen X, Cui C, Hou J, Wang J. Fu W, et al. Among authors: cui c. Ann Hematol. 2024 Nov;103(11):4835-4836. doi: 10.1007/s00277-024-06020-3. Ann Hematol. 2024. PMID: 39311958 Free PMC article. No abstract available.
Real-world analysis of treatment patterns, effectiveness, and safety of daratumumab-based regimens in Chinese patients with newly diagnosed or relapsed/refractory multiple myeloma.
Wang L, Yang W, Wang Y, Niu T, Fu R, Zhong Y, Qian W, Ding K, Sun K, Liu H, Fang B, Liu H, Li Y, Yang Y, Zhuo J, Chen X, Cui C, Lu J. Wang L, et al. Among authors: cui c. BMC Cancer. 2025 May 7;25(1):836. doi: 10.1186/s12885-025-13925-3. BMC Cancer. 2025. PMID: 40335949 Free PMC article.
The Secretome of Human Trophoblast Stem Cells Attenuates Senescence-Associated Traits.
Abdelmohsen K, Martindale JL, Rossi M, Shin CH, Pal A, Munk R, Salamini-Montemurri M, Baranzini M, Arends EM, Mustapic M, Lee Y, Lee JN, Popma SH, Hu J, Duda N, Nogueras-Ortiz CJ, Kapogiannis D, Cui CY, Gorospe M. Abdelmohsen K, et al. Among authors: cui cy. Aging Cell. 2026 Feb;25(2):e70368. doi: 10.1111/acel.70368. Aging Cell. 2026. PMID: 41521531 Free PMC article.
5,018 results